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EDITORIAL COMMENT
Eradication of Viral Myocarditis
Is There Hope?*
Christina Baboonian, PHD,
William McKenna, MD, DSC, FRCP, FACC
London, United Kingdom
Adenoviruses acquired celebrity status when viral constructs
began to be used as gene transfer vectors in man. Within a
short period of time a virus ignored by all except dedicated
virologists became known worldwide. A review of the
current literature, however, reflects an omission. Adenovi-
ruses as infectious agents are still very much ignored. In this
issue of the Journal, Bowles et al. (1) attempt to address the
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imbalance and report on a multicenter study of adenovirus
and enterovirus infections in patients with myocarditis and
dilated cardiomyopathy (DCM). Their finding that adeno-
viral deoxyribonucleic acid (DNA) is present in 23% of
myocarditis and 12% of DCM patients is a cause for
concern and sufficient to justify the conclusions of the
investigators that infections with these agents deserve at-
tention, and that a treatment or prevention strategy must be
considered.
COXSACKIE VIRUS INFECTION
Viral myocarditis has for almost 50 years been synonymous
with Coxsackie B virus infection. Extensive attempts have
been made to search for evidence of enteroviral involvement
in the myocardium and study the pathogenesis of the disease
(2). Why a common infection might be asymptomatic in
most individuals and result in myocarditis in others is not
known, but cardiotropic strains of Coxsackie viruses have
been held to account for the virulence pattern observed in
the community (3). Differences in the affinity of the virus for
cellular receptors may also have a deciding role in infectivity
and pathogenesis of enteroviruses, with some strains better
able to spread in vivo (4). A significant breakthrough in
understanding the mechanism of virus-induced disease
came with the discovery that Coxsackie viral protease can
cleave dystrophin and hence adversely affect myocyte struc-
tural integrity (5). Understanding the pathogenesis of en-
teroviral infection provided fresh incentive to continue the
work. Case reports of Coxsackie viral myocarditis are still
presented (6,7), and large-scale studies addressing the inci-
dence of enteroviral involvement in disease continue to be of
interest (8–10). Although viruses other than enteroviruses
have periodically appeared in the literature, and influenza
(11,12), parvoviruses (13,14), hepatitis C (15), and human
immunodeficiency virus (16,17) among others (18) have all
been related to myocardial disease, Coxsackie viruses have to
date maintained the monopoly.
An observation long forgotten until re-instigated by
Longberg-Holm et al. in 1976 (19) was a report published
in the Journal of Bacteriology 10 years earlier (20) stating that
two unrelated viruses, Coxsackie and adenoviruses, use
common cellular receptors for entry. It took 12 more years
before the common receptor for the two agents was char-
acterized (21). In hindsight, the information is critical in
understanding how two diverse agents, one a ribonucleic
acid and one a DNA virus, with replication strategies that
bear little resemblance to one another, are both capable of
infecting the myocardium. Despite more than three decades
of knowledge that both agents can enter the same cells and
the understanding that adenoviruses are cardiotropic and
able to induce myocarditis in mice (22), until recently no
concerted effort had been made to look for adenoviruses in
the heart tissue. Although case reports dating back to 1971
suggest an association between adenoviruses and myocardi-
tis (23) and isolated incidences of infection leading to
myocardial disease are recorded in the literature (24–28),
the extent of the involvement of these agents in cardiomy-
opathy is unclear.
ADENOVIRAL MYOCARDITIS
Two early studies, one conducted in 1968 by Berkovich et
al. (29) and one by Gardiner and Short in 1973 (30), present
evidence of the scale of the problem with adenoviral
myocarditis. The reports relate to both pediatric and adult
cases of disease; using virus culture and serological markers
of infection suggests that adenoviruses are associated with
17% of pediatric and 3% of adult cases of myocarditis. A 4%
association of infection with adult disease was later con-
firmed by Vikerfors et al. in 1988 (31). Towbin’s laborato-
ries started a systematic evaluation of human cardiac tissue
for evidence of viral presence in 1994 and reported that 15
of 38 pediatric hearts taken from patients with myocarditis
and examined by polymerase chain reaction (PCR) had
adenoviral nucleic acids (32). Investigations in children
continued, and the same team reported in 1999 that 9% of
patients with myocarditis are infected with this agent (11).
Two other studies relate to myocardial infection in children.
One study carried out by Shimizu et al. (33) reported eight
cases of sudden death in infants and found one infected
child; the second was a study by Calabrese et al. (34) who,
using PCR, found over a third of the pediatric myocarditis
cases to be associated with adenoviruses. A review of the
literature suggests that, although the number of reported
studies in children is small and mainly presented as case
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reports, the findings are consistent. This is not the case with
association studies conducted in adults (Tables 1 and 2).
Four recent studies (35–38) reported the presence of viral
DNA by PCR in patients with myocarditis and cardiomy-
opathy. All four studies originate from teams collaboratively
engaged in the report presented in the current issue of
the Journal (1) and show incidence of infection ranging from
2.5% (37) to 16.6% (35). Opposing views are expressed by
others, and Grumbach et al. (39) studying 31 cases, Fujioka
et al. (40) 26 cases, and Cioc and Nuovo (25) 11 cases of
adult myocarditis and DCM found no adenoviral DNA in
the myocardium. Serological studies conducted by Drescher
et al. (41) on 43 adult and 8 childhood cases of sudden death
also found no evidence of adenoviral infection.
Differences in the adult and pediatric populations are not
entirely unexpected. Adenoviruses are ubiquitous agents
with close to 50 serotypes, approximately a third of which
commonly cause disease. Infections are widespread and
often transmitted by fecal-oral or respiratory route early in
life. By the age of two years there is evidence that a very high
proportion of children carry the agent in lymphocytes
separated from tonsil tissue (42). Although infections are
often asymptomatic, approximately 5% to 10% of pediatric
respiratory infections are due to adenoviral infections, with
outbreaks facilitated in environments where young people
remain in close proximity. By five years of age almost all
children have been infected by at least one adenovirus. A
matter of crucial importance is that epidemiological studies
have shown serotypes 1, 2, and 5 to be more common in
children, whereas serotypes 4, 7, and 21 cause respiratory
infections in adults (43). When Pauschinger et al. (38) typed
the adenoviruses found in adults with left ventricular dys-
function, type 2 viruses were identified. Later, Bowles et al.
(35) found adenovirus type 5 in patients with arrhythmo-
genic right ventricular dysplasia. It is possible that the high
incidence of type 2 infection in the young population and
the increased carriage rate of the virus in leukocytes in this
group predisposes them to cardiac manifestations. In the
present report by Bowles et al. (1) the proportion of young
patients under the age of 13 that have adenovirus-associated
myocarditis is between 24% and 29%. This figure is reduced
to 14% to 16% in adolescents and adults, a pattern that may
correlate with the incidence of infection in this group.
Prevalence of group C adenoviral DNA in human mucosal
lymphocytes has been shown to be highest in two-year-olds.
Thereafter, a decrease occurs in the amount of viral DNA
with age (42). This pattern agrees with the report presented
in the current issue of the Journal.
The higher proportion of children with adenovirus infec-
tions of the myocardium may also reflect the absence of
prior cross-reactive immunity. Nearly all adults have sero-
logic evidence of past exposure, and over 90% have memory
T cells that respond to adenoviruses (44). It is possible that
infection with one serotype may offer protection against
others, allowing adults to escape viremia when infected with
cardiotropic agents. Evidence for this is presented in a study
Table 1. Association of Adenoviruses With Myocarditis and Cardiomyopathy in Adults
Study, Year (Ref.) Cases Investigated Methods Used
No. of
Patients
No. Found
Positive
Gardiner and Short, 1973 (30) Myocarditis or pericarditis 60 2 (3.3%)
Karjalainen et al., 1983 (46) Military recruits/subclinical/ECG changes Serology 126 19 (15.1%)
Karjalainen et al., 1986 (47) Military recruits/subclinical/ECG changes Serology 27 12 (44.4%)
Drescher et al., 1987 (41) Sudden death Serology 51 0 (0%)
Vikerfors et al., 1988 (31) Myocarditis Serology 24 1 (4.2%)
Grumbach et al., 1999 (39) Myocarditis/DCM PCR 31 0 (0%)
Pauschinger et al., 1999 (38) Left ventricular dysfunction PCR 94 12 (12.8%)
Fujioka et al., 2000 (40) DCM PCR 26 0 (0%)
Davydova et al., 2000 (36) Myocarditis/DCM PCR 33 1 (3.0%)
Hufnagel et al., 2000 (37) Myocarditis PCR 526 13 (2.5%)
Bowles et al., 2002 (35) ARVD cardiomyopathy PCR 12 2 (16.6%)
Cioc et al., 2002 (25) Myocarditis/sudden death In situ hybridization 11 0 (0%)
Summary 1,021 62 (6.1%)
ARVD  arrhythmogenic right ventricular dysplasia/cardiomyopathy; DCM  dilated cardiomyopathy; PCR  polymerase chain reaction.
Table 2. Association of Adenoviruses With Myocarditis and Cardiomyopathy in Children
Study, Year (Ref.) Cases Investigated Methods Used
No. of
Patients
No.
Found
Positive
Berkovich et al., 1968 (29) Myocarditis Virus isolation (stool samples) 12 2 (17%)
Martin et al., 1994 (32) Myocarditis PCR 38 15 (39%)
Shimizu et al., 1995 (33) Sudden infant death/myocarditis/pericarditis PCR 8 1 (12%)
Akhtar et al., 1999 (11) Pneumonia and myocarditis PCR 32 3 (9%)
Calabrese et al., 2002 (34) Myocarditis PCR 26 9 (36%)
Summary 116 30 (25.9%)
PCR  polymerase chain reaction.
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conducted by Smith et al. (45), who have shown human
cytotoxic T lymphocytes generated to react against one
serotype of adenovirus are capable of lysing cells infected
with other subgroups. Antigenic similarities between strains
within one adenovirus subfamily may therefore influence
outcome of an infection. Whether an infection remains
subclinical or develops into full-blown disease could ulti-
mately depend on which serotype one is exposed to first.
Adenovirus infections do not often result in disseminated
disease. The presence of viral DNA in circulating and
mucosal lymphocytes, however, suggests that the virus may
not be confined to the site of infection (42). How frequently
do respiratory and gastrointestinal infections culminate in
viral entry into circulation is unknown. If this is a frequent
event, the virus carried by lymphocytes will have access to
myocytes with receptors encouraging viral entry. What
proportion of such cases present as overt myocarditis is also
uncertain. Some evidence suggests that myocardial involve-
ment following acute infection may be frequent. Karjalainen
et al. (46,47) assessed military recruits in two separate
studies in 1983 and 1986 for evidence of recent infection
using raised antibody levels as markers. In patients with
adenovirus infection, serial electrocardiographic changes
were noted, with ST-segment elevation and T-wave inver-
sion lasting for four days or more.
Finally, whereas mortality is associated with some respi-
ratory and gastrointestinal infections and disease in military
recruits has proved to be a major inconvenience, adenovi-
ruses have not been on top of the priority list for preventa-
tive measures. Involvement of these viruses in myocarditis
alters our perspective and places adenoviruses alongside
infectious agents such as measles and mumps. Hofling et al.
(48) conclude a review article on progress toward vaccines
against viruses that cause heart disease by expressing doubts
that the marketplace will support the development of such
vaccines. Our view is a little more optimistic. The patho-
genic potential of agents that infect us all must not be
ignored. Replication of defective adenoviruses, used as gene
delivery vehicles, provide excitement and bring research in
basic virology into focus. But there is a more sobering aspect
to native adenoviruses that we must not forget: The conse-
quences of infection, with cardiac involvement, can be
death.
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